Oncology
Latest news
886 articles · 20 / page
Tumor Morcellation, Not Minimally Invasive Surgery Alone, Drives Worse Disease-Free Survival in Stage I Adult Granulosa Cell and Sertoli-Leydig Cell Tumors
In stage I ovarian sex cord-stromal tumors, stage IC and tumor morcellation were independently associated with recurrence, while minimally invasive surgery itself was not after adjustment.
Early HbA1c Control After Type 2 Diabetes Diagnosis May Shape Long-Term Cancer Risk
In a large Hong Kong cohort with newly diagnosed type 2 diabetes, higher early HbA1c exposure was associated with greater long-term cancer risk, suggesting that glycaemic control soon after diagnosis may matter more than later improvement.
Language Barriers and Treatment Delays Emerge as Modifiable Threats in Early-Onset Colorectal Cancer
A large Texas registry study found that treatment delays beyond 6 weeks were independently associated with worse survival in early-onset colorectal cancer, with language barriers identified as a potentially modifiable contributor.
S1P Receptor Modulation Restores FLT3 Inhibitor Sensitivity in NRAS-Mutated FLT3-ITD Acute Myeloid Leukemia
Preclinical data suggest fingolimod and mocravimod can resensitize NRAS-mutated FLT3-ITD AML to FLT3 inhibitors by suppressing ERK-SPHK1-AKT signaling, including activity in patient blasts and an orthotopic mouse model.
Immune Checkpoint Inhibitor-Associated Uveitis: Comparative Risk Across Cancers and Drug Classes
A multicenter study found that immune checkpoint inhibitor–associated uveitis risk varies by cancer type and drug class, with melanoma showing the highest intrinsic risk and RCC risk largely linked to ipilimumab/nivolumab exposure.
Transcriptome Profiling With CCNA2 and E2F1 May Identify Platinum Insensitivity and Refine Prognosis in Endometrial Cancer
TCGA-based transcriptome analysis suggests high CCNA2 and E2F1 expression marks poor progression-free survival and probable platinum insensitivity in endometrial cancer, supporting pretreatment molecular stratification and alternative thera
Y90 Radioembolization as a Bridge to Liver Transplantation in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
Y90 radioembolization downstaged about one-quarter of HCC patients with portal vein tumor thrombosis to transplant eligibility, and those who received liver transplantation had markedly better cancer-related outcomes and survival.
Adipocyte-Driven Immunometabolic Suppression in Pancreatic Cancer: The 12,13-DiHOME/PPARγ/TAN Axis
This review explores how tumour-infiltrating adipocytes release 12,13-DiHOME to trigger neutrophil ferroptosis and CXCL2 production, ultimately subverting CD8+ T cell-mediated immunity in pancreatic ductal adenocarcinoma.
Quorum-Sensing Molecules Elevated in Long-Standing Ulcerative Colitis May Help Drive Colitis-Associated Cancer
Bacterial quorum-sensing molecules, especially C6-scAHL, were elevated in long-standing ulcerative colitis and promoted colon tumor growth in mice, suggesting a new microbiome-driven pathway for colitis-associated cancer.
Detectable Antithyroglobulin Antibodies Above the Assay LOQ Signal Higher Recurrence Risk in Papillary Thyroid Carcinoma Despite Undetectable Thyroglobulin
In papillary thyroid carcinoma treated with thyroidectomy and RAI, TgAb levels above the assay’s limit of quantification identified patients with higher long-term recurrence risk despite undetectable serum thyroglobulin.
Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial
Adding fovinaciclib to first-line aromatase inhibitor therapy significantly prolonged progression-free survival in hormone receptor-positive, ERBB2-negative advanced breast cancer with manageable toxicity and preserved quality of life.
Twice-Weekly All-Oral Ixazomib, Pomalidomide, and Dexamethasone Shows Durable Activity in Relapsed/Refractory Multiple Myeloma
A phase I/II study suggests twice-weekly ixazomib plus pomalidomide-dexamethasone is a feasible all-oral option in relapsed/refractory multiple myeloma, with a 65.8% response rate at the RP2D and manageable hematologic toxicity.
Anti-CD117 Conditioning With Briquilimab Shows Feasibility and Stem-Cell Depletion in Older Adults Undergoing Allogeneic Transplant for High-Risk AML and MDS
A phase 1 trial suggests briquilimab can be safely added to nonmyeloablative conditioning before allogeneic transplant in older adults with high-risk AML or MDS, with biologic evidence of hematopoietic stem/progenitor cell depletion and enc
Pancreatic Cancer Risk During IPMN Surveillance Is About 10-Fold Higher Than in the General Population
A SEER-matched analysis found that patients undergoing IPMN surveillance have a markedly elevated malignancy risk, with substantial heterogeneity by duct dilation, obesity, age, and cyst features.
Pancreatic Cancer Risk During IPMN Surveillance: A SEER-Based Comparison
A SEER-based study found IPMN surveillance patients have about 10 times higher pancreatic cancer risk than the general population, with highest risk in those with main duct dilation or obesity.
More Than Half of Patients With Atypical Endometrial Hyperplasia Had Occult Cancer at Hysterectomy in a Minority-Enriched Urban Cohort
A single-center retrospective study found unexpectedly high rates of concurrent endometrial carcinoma and Mayo-criteria risk features among patients with atypical endometrial hyperplasia in a predominantly racial and ethnic minority populat
Longitudinal Risk for Suicidal Self-Directed Violence Among Veterans With Cancer
A national study of veterans with cancer found elevated suicide-related risk that persisted for years, especially among younger, unmarried, frail, or mentally ill patients and those with certain cancers such as central nervous system and th
Targeting Ibrutinib Resistance Pathways with miR-28 in ABC-DLBCL
miR-28 suppresses the emergence of ibrutinib resistance in ABC-DLBCL by disrupting clonal selection and dampening mitochondrial and mTOR signaling, with promising preclinical nanoparticle delivery results.
When Severe Mental Illness Meets Lung Cancer: Why Equal Treatment Still Isn’t Guaranteed
A large Japanese study found that people with schizophrenia spectrum disorders were less likely to receive several standard treatments for non-small cell lung cancer, underscoring a persistent and preventable gap in cancer care.
Patients With Schizophrenia Spectrum Disorder Are Less Likely to Receive Stage-Appropriate Treatment for Non-Small Cell Lung Cancer in Japan
A nationwide Japanese cohort study found that patients with schizophrenia spectrum disorder and NSCLC presented with more advanced disease and were less likely to receive surgery, adjuvant chemotherapy, or systemic therapy.
Browse by specialty
Open language-specific specialty feeds and department pages.